Supply Chain Featured Content news and information

Desperate after a decade of trial and error to make the connection that could usher in a new generation of anti-HIV drugs, University of Washington researchers threw the scientific version of a Hail Mary pass.
FULL STORY »

A patient balks at paying $50 for a dose of antibiotics. However, that same patient has no issue paying $50,000 for an oncology drug that may extend life for a few weeks.
FULL STORY »

Last year, the Utah-based SelectHealth insurance company paid $1 million to provide just five patients with the critical enzyme-replacement drug Cerezyme.
FULL STORY »

At least seven of the 35 new drugs approved by the Food and Drug Administration last year cost $9,000 or more per month as manufacturers turn to developing high-priced specialty drugs to shore up bottom lines eroding from the expiration of patents on best-selling drugs that treat common conditions.
FULL STORY »

Group purchasing organizations say the medical device industry is passing along the costs of a controversial excise tax to healthcare providers.
FULL STORY »

In one of the few pieces of significant legislation to win bipartisan support in 2012, Congress reauthorizes the Food and Drug Administration's user-fee acts for the drug and medical device industries and establishes first-time user-fee programs for the biosimilars and generic drug sectors.
FULL STORY »

Hospitals will likely pay higher prices for some medical devices as manufacturers seek to pass through the cost of an impending excise tax to providers.
FULL STORY »

Manufacturers and patient advocates say providers should inform women if they have dense breast tissue and in many cases offer supplemental breast cancer screening methods for these patients, but some radiologists are pressing for more data about the practices.
FULL STORY »

The growing adoption of complex health technology in hospitals is expected to reduce errors and improve the quality of care, but increased utilization of health IT-based technologies comes with its own set of risks for healthcare providers.
FULL STORY »

Just when they might have thought they were in the clear, people recovering from meningitis in an outbreak caused by a contaminated steroid drug have been struck by a second illness.
FULL STORY »